H.C. Wainwright raised the firm’s price target on Allogene Therapeutics (ALLO) to $12 from $8 and keeps a Buy rating on the shares. The firm views the MRD-negativity rate in the ALPHA3 trial as “risk-mitigating” for the primary endpoint.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics price target raised to $8 from $5 at Citizens
- Cellectis highlights Allogene ALPHA3 trial data, potential milestone payments
- Allogene Therapeutics Launches New Underwritten Common Stock Offering
- Allogene Therapeutics announces $175M common stock offering
- Midday Fly By: Goldman reports Q1 beat, Baker Hughes to sell Waygate